Skip to main content

Table 3 A summary of the reporting by ethnicity through different stages of COVID-19 clinical trials, including those approached, screened and deemed eligible or ineligible for inclusion; those enrolled in the trial; those followed up at the primary end point and longest follow-up; and reporting of effect estimates

From: Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis

Stage of trial

No. of trials reporting by ethnicity (no. participants)

References

No. of trials reporting as “White”, “BAME”, “non-white”, “Other” (no. participants)

References

Approached for inclusion

0

 

0

 

Screened for inclusion

0

 

7 (60,179)

[8, 10, 13, 17, 18, 23, 26]

Eligible for inclusion

0

 

7 (60,179)

[8, 10, 13, 17, 18, 23, 26]

Ineligible for inclusion

0

 

7 (60,179)

[8, 10, 13, 17, 18, 23, 26]

Enrolled in trial

17 (52,747)

[1,2,3,4, 6, 7, 12, 14,15,16, 19, 20, 24, 25, 27,28,29]

11 (64,722)

[5, 8,9,10,11, 13, 17, 18, 23, 26, 30]

Followed up at primary endpoint

0

 

9 (64,434)

[8,9,10,11, 13, 17, 18, 23, 26]

Followed up at longest follow-up

0

 

0

 

Effect estimates

0

 

11 (79,740)

[1, 8,9,10,11, 13, 17,18,19, 23, 26]